Please ensure Javascript is enabled for purposes of website accessibility

Should You Buy Ocugen Stock in March?

By Jim Halley - Mar 8, 2021 at 10:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ocugen has set record highs this month on news regarding COVID-19 vaccine Covaxin. Is it too late to get in on the stock?

Shares in Ocugen (OCGN 8.14%), a Malvern, Penn., biopharmaceutical company, were below $0.30 a share as recently as Dec. 15, and now, they're just above $8 a share. That's after climbing to $10 a share earlier this week. Over the past three months, the company's shares have risen more than 2,500%.

What's behind all of this investor enthusiasm? It isn't the company's balance sheet, at least not yet. Ocugen is a clinical-stage company whose early-stage gene therapies are aimed at preventing or suppressing inherited eye diseases that cause blindness.

Its pipeline includes just three therapies, led by OCU400, which has four U.S. Food and Drug Administration (FDA) orphan drug designations with the potential to treat more than 150 gene mutations of retinitis pigmentosa, a disease that causes a loss of cells in the retina and can lead to blindness.

Stethoscope sitting on pile of hundred dollar bills.

Image source: Getty Images.

Looking at the financials

The company reported no revenue for the third quarter and, so far, has only $42,600 in revenue for the year. Through nine months, the company shows a net loss of $18 million, which is an improvement at least over the $32.6 million it lost in the first nine months of 2019.

What has investors excited is Ocugen's deal with India's Bharat Biotech to bring that company's COVID-19 vaccine, Covaxin, to the U.S. market. Ocugen, for its part, is taking the vaccine through all the levels of U.S. regulatory approval, in return for 45% of the profits derived from the vaccine.

On March 3, Ocugen announced preliminary positive data in a phase 3 trial for Covaxin, with the vaccine showing 81% effectiveness in fighting COVID-19. The vaccine has already been given emergency use approval in India, and the early signs on its phase 3 trial show it might have a good chance to be approved for use in the U.S.

The vaccine is inactivated, made up of dead coronavirus. When injected into the body, that dead coronavirus is designed to stimulate an antibody response, making the person be able to ward off an actual coronavirus infection.

OCGN Chart

OCGN data by YCharts

Coming late to the party

If approved, Covaxin would be the fourth COVID-19 vaccine approved in the U.S., behind the Pfizer-BioNTech, Moderna, and Johnson & Johnson vaccines. The question is, how well would the vaccine be adopted here?

One big problem for Covaxin is that it seems to have few advantages over already approved vaccines. Like the Pfizer-BioNTech and Moderna vaccines, Covaxin would be given in two doses, weeks apart, and must be refrigerated. The early results show it being less effective than those vaccines, however, with the Pfizer-BioNTech vaccine demonstrating 95% efficacy, compared with 94% for Moderna's. Covaxin has a better efficacy than Johnson & Johnson's 66%, but that one requires only one shot and does not need to be refrigerated.

There also may be some resistance to approving a vaccine that was controversial when it was approved in India in January, before what many felt was adequate review. On top of that, AstraZeneca also has a vaccine that is in phase 3 trials.

Still, the slow production of vaccines in the United States has hampered the rollout, so another vaccine, particularly one that is already being manufactured in large quantities, may be welcomed by health authorities.

What investors need to be concerned with regarding Ocugen

Covaxin's positive trial is great news for Ocugen, which could use additional revenue. The company has $19.3 billion in cash as of Sept. 30, but more incoming revenue would help it finance its research and development for years to come.

However, the stock's rise over the past three months means whatever benefits Ocugen may get from Covaxin's approval may already be priced in. The slide back from $10 to $8 a share shows that healthcare investors may already be getting wary of how long the bump can last.

Ocugen's therapies ultimately may be very profitable, but with all of them in clinical development or early-stage trials, that's a long way away. The bigger concern is that if Covaxin isn't approved, new investors will be left with a plummeting stock that, based on its fundamentals, is way overpriced.

My advice is to stay away from the stock, at least until its own pipeline begins to pay off.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
$2.39 (8.14%) $0.18
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$10,580.00 (0.32%) $34.00
Pfizer Inc. Stock Quote
Pfizer Inc.
$53.91 (-0.15%) $0.08
Johnson & Johnson Stock Quote
Johnson & Johnson
$181.09 (0.91%) $1.63
Moderna, Inc. Stock Quote
Moderna, Inc.
$147.66 (8.73%) $11.86
BioNTech SE Stock Quote
BioNTech SE
$166.96 (5.57%) $8.81

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.